|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of ACSL1 mRNA |
CTD |
PMID:19520133 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of ALOX5 mRNA] |
CTD |
PMID:21877189 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of CEBPA mRNA; glucosamine 6-O-sulfate results in decreased expression of CEBPA protein |
CTD |
PMID:19520133 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of CHUK protein] |
CTD |
PMID:21877189 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of FABP4 mRNA |
CTD |
PMID:19520133 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of FAS mRNA |
CTD |
PMID:19520133 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:21877189 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:21877189 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:21877189 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of LEP mRNA |
CTD |
PMID:19520133 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of LIPE mRNA |
CTD |
PMID:19520133 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of LPL mRNA |
CTD |
PMID:19520133 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21877189 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21877189 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:21877189 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:21877189 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:21877189 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A protein] |
CTD |
PMID:21877189 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plin1 |
perilipin 1 |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of PLIN1 mRNA |
CTD |
PMID:19520133 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of PPARG mRNA; glucosamine 6-O-sulfate results in decreased expression of PPARG protein |
CTD |
PMID:19520133 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:21877189 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein] |
CTD |
PMID:21877189 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
glucosamine 6-O-sulfate results in decreased expression of SREBF1 mRNA; glucosamine 6-O-sulfate results in decreased expression of SREBF1 protein |
CTD |
PMID:19520133 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; glucosamine 6-O-sulfate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21877189 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Carrageenan results in increased phosphorylation of AKT1 protein fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:26418808 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions decreases expression |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of ALB protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of ALB protein] |
CTD |
PMID:34789018 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Anxa1 |
annexin A1 |
affects response to substance multiple interactions |
ISO |
ANXA1 protein affects the susceptibility to Carrageenan ANXA1 protein affects the susceptibility to [Dexamethasone co-treated with Carrageenan] |
CTD |
PMID:12475898 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Apcs |
amyloid P component, serum |
increases expression |
EXP |
Carrageenan results in increased expression of APCS protein |
CTD |
PMID:22330755 |
|
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO EXP |
fucoxanthin inhibits the reaction [Carrageenan results in decreased activity of CAT protein] caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased activity of CAT protein] |
CTD |
PMID:26418808 PMID:28844677 PMID:34789018 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL2 protein] |
CTD |
PMID:12444156 PMID:20383154 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL3 protein] |
CTD |
PMID:12444156 PMID:20383154 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO EXP |
Carrageenan results in increased expression of CCL5 protein isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein] |
CTD |
PMID:12444156 PMID:14654164 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cma1 |
chymase 1 |
multiple interactions increases expression |
EXP |
adelmidrol inhibits the reaction [Carrageenan results in increased expression of CMA1 protein] |
CTD |
PMID:18429935 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Crp |
C-reactive protein |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of CRP protein caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of CRP protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of CRP protein] |
CTD |
PMID:34789018 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases secretion increases expression |
EXP ISO |
IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of CXCL2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein] |
CTD |
PMID:12444156 PMID:14654164 PMID:21549112 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
Carrageenan results in increased expression of CXCL1 protein |
CTD |
PMID:12444156 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Carrageenan results in increased expression of EGR1 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein] |
CTD |
PMID:22561171 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen promotes the reaction [Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]]; Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Urethane inhibits the reaction [Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]] |
CTD |
PMID:1327382 PMID:11164833 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gal |
galanin and GMAP prepropeptide |
decreases response to substance |
ISO |
GAL protein results in decreased susceptibility to Carrageenan |
CTD |
PMID:17999197 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gpr132 |
G protein-coupled receptor 132 |
increases expression |
ISO |
Carrageenan results in increased expression of GPR132 mRNA |
CTD |
PMID:19602228 |
|
NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168
|
|
G |
Gpr4 |
G protein-coupled receptor 4 |
increases expression |
ISO |
Carrageenan results in increased expression of GPR4 mRNA |
CTD |
PMID:19602228 |
|
NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599
|
|
G |
Gpr65 |
G-protein coupled receptor 65 |
increases expression |
ISO |
Carrageenan results in increased expression of GPR65 mRNA |
CTD |
PMID:19602228 |
|
NCBI chr 6:117,515,786...117,536,514
Ensembl chr 6:117,515,648...117,536,512
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of HMOX1 protein] Carrageenan results in decreased expression of HMOX1 mRNA; Carrageenan results in decreased expression of HMOX1 protein |
CTD |
PMID:28844677 PMID:34789018 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
EXP |
Carrageenan results in increased expression of HSPA1A protein |
CTD |
PMID:15860553 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein] Carrageenan results in increased expression of ICAM1 mRNA; Carrageenan results in increased expression of ICAM1 protein |
CTD |
PMID:11181422 PMID:14709329 PMID:22330755 PMID:27803785 PMID:34789018 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
increases secretion multiple interactions increases expression |
EXP ISO |
Carrageenan results in increased secretion of IL10 protein indole-3-guanylhydrazone hydrochloride promotes the reaction [Carrageenan results in increased secretion of IL10 protein]; Indomethacin promotes the reaction [Carrageenan results in increased secretion of IL10 protein] Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL10 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL10 protein]; Thioctic Acid promotes the reaction [Carrageenan results in increased expression of IL10 mRNA] |
CTD |
PMID:11181422 PMID:19735303 PMID:28844677 PMID:29499192 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions decreases expression |
ISO |
Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]; Dexamethasone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Dexamethasone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]; Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]; Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]] |
CTD |
PMID:12182845 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion increases expression multiple interactions |
ISO EXP |
Carrageenan results in increased secretion of IL1B protein Carrageenan results in increased expression of IL1B mRNA; Carrageenan results in increased expression of IL1B protein 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of IL1B protein] 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of IL1B protein] |
CTD |
PMID:11181422 PMID:16368644 PMID:17320857 PMID:20383154 PMID:21549112 PMID:22330755 PMID:23774260 PMID:23872256 PMID:29499192 PMID:34789018 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO EXP |
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL6 protein] 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Diclofenac inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL6 protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of IL6 protein] |
CTD |
PMID:11181422 PMID:20383154 PMID:22330755 PMID:23774260 PMID:24412305 PMID:28844677 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions increases expression |
EXP |
procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of KLK3 protein] |
CTD |
PMID:28844677 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Carrageenan results in increased phosphorylation of MAPK1 protein fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26418808 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions increases expression |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA] |
CTD |
PMID:34789018 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26418808 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of MMP9 protein adelmidrol inhibits the reaction [Carrageenan results in increased expression of MMP9 protein] |
CTD |
PMID:18429935 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity increases expression |
EXP |
adelmidrol inhibits the reaction [Carrageenan results in increased activity of MPO protein]; arvelexin analog inhibits the reaction [Carrageenan results in increased expression of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Diclofenac inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Ibuprofen inhibits the reaction [Carrageenan results in increased expression of MPO protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Carrageenan results in increased activity of MPO protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased activity of MPO protein] Carrageenan results in increased expression of MPO mRNA; Carrageenan results in increased expression of MPO protein |
CTD |
PMID:9890637 PMID:15860553 PMID:18429935 PMID:23872256 PMID:24412305 PMID:25451575 PMID:34789018 More...
|
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Methylnitrosourea co-treated with Carrageenan] results in increased expression of MT1 protein |
CTD |
PMID:15928667 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization decreases expression multiple interactions |
EXP |
Carrageenan affects the localization of NFE2L2 protein Carrageenan results in decreased expression of NFE2L2 mRNA caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan affects the localization of NFE2L2 protein] |
CTD |
PMID:28844677 PMID:34789018 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of NFKB1 mRNA caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34789018 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein] |
CTD |
PMID:22561171 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of NGF protein Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NGF protein] |
CTD |
PMID:10653021 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity |
EXP ISO |
adelmidrol inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of NOS2 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA] fucoxanthin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein] Carrageenan results in increased activity of NOS2 protein Carrageenan results in increased expression of NOS2 mRNA; Carrageenan results in increased expression of NOS2 protein |
CTD |
PMID:7542281 PMID:9890637 PMID:15860553 PMID:18429935 PMID:22330755 PMID:26418808 PMID:27803785 PMID:34789018 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
EXP |
Carrageenan results in decreased expression of NQO1 protein procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of NQO1 protein] |
CTD |
PMID:28844677 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
decreases expression |
ISO |
Carrageenan results in decreased expression of OPRM1 protein |
CTD |
PMID:30763598 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
EXP |
[(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) binds to and results in decreased activity of P2RX7 protein] which results in decreased susceptibility to Carrageenan |
CTD |
PMID:16982702 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of PECAM1 protein adelmidrol inhibits the reaction [Carrageenan results in increased expression of PECAM1 protein] |
CTD |
PMID:18429935 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions increases expression |
EXP |
arvelexin analog inhibits the reaction [Carrageenan results in increased expression of PTGES protein] |
CTD |
PMID:17258197 PMID:25451575 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptges2 |
prostaglandin E synthase 2 |
multiple interactions increases activity |
EXP |
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone |
CTD |
PMID:19934399 |
|
NCBI chr 3:15,690,501...15,697,688
Ensembl chr 3:15,690,501...15,697,688
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; dragon's blood inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Ketorolac inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; nimesulide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; triflusal inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] fucoxanthin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] Carrageenan results in increased expression of PTGS2 mRNA; Carrageenan results in increased expression of PTGS2 protein |
CTD |
PMID:10101034 PMID:14654164 PMID:15860553 PMID:17258197 PMID:18814970 PMID:19735303 PMID:22198006 PMID:24337631 PMID:26418808 PMID:27803785 PMID:34789018 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation increases expression increases localization multiple interactions |
ISO EXP |
Carrageenan results in increased phosphorylation of RELA protein Carrageenan results in increased expression of RELA protein Carrageenan results in increased localization of RELA protein caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of RELA protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased localization of RELA protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of RELA protein] |
CTD |
PMID:21549112 PMID:22561171 PMID:34789018 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Selp |
selectin P |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of SELP protein imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of SELP protein] |
CTD |
PMID:11181422 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sstr4 |
somatostatin receptor 4 |
decreases response to substance |
ISO |
SSTR4 results in decreased susceptibility to Carrageenan |
CTD |
PMID:19622729 |
|
NCBI chr 3:135,854,826...135,856,689
Ensembl chr 3:135,854,826...135,856,689
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases expression |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA] |
CTD |
PMID:34789018 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases secretion |
ISO |
Carrageenan results in increased secretion of TGFB1 protein |
CTD |
PMID:16368644 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; Carrageenan results in decreased expression of and affects the localization of TJP1 protein; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein] |
CTD |
PMID:22561171 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Carrageenan results in increased secretion of TNF protein 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; adelmidrol inhibits the reaction [Carrageenan results in increased expression of TNF protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of TNF protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of TNF protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of TNF protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Rutin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of TNF protein] Carrageenan results in increased expression of TNF mRNA; Carrageenan results in increased expression of TNF protein 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of TNF protein]; diaoxinxuekang inhibits the reaction [Carrageenan results in increased expression of TNF protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of TNF protein] |
CTD |
PMID:11181422 PMID:12444156 PMID:14654164 PMID:16368644 PMID:17320857 PMID:18429935 PMID:20383154 PMID:21549112 PMID:22330755 PMID:23774260 PMID:23872256 PMID:24412305 PMID:26571085 PMID:28844677 PMID:29499192 PMID:34789018 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
EXP |
Carrageenan results in increased expression of VCAM1 mRNA Dexamethasone inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Arsb |
arylsulfatase B |
decreases abundance |
ISO |
ARSB protein results in decreased abundance of Chondroitin Sulfates |
CTD |
PMID:29794138 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates |
CTD |
PMID:21436127 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to BDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
C3 |
complement C3 |
increases cleavage |
ISO |
Chondroitin Sulfates analog results in increased cleavage of C3 protein |
CTD |
PMID:18434646 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C5 |
complement C5 |
increases cleavage |
ISO |
Chondroitin Sulfates analog results in increased cleavage of C5 protein |
CTD |
PMID:18434646 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Chondroitin Sulfates inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:12736501 PMID:15089041 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects binding |
ISO |
Chondroitin Sulfates binds to CCL2 protein |
CTD |
PMID:16385517 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL9 protein]; Chondroitin Sulfates promotes the reaction [CTSB protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide] |
CTD |
PMID:25833952 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSK protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL3 protein] |
CTD |
PMID:25833952 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL2 protein] |
CTD |
PMID:25833952 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSS protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL2 protein] |
CTD |
PMID:25833952 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSK protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL10 protein]; Chondroitin Sulfates inhibits the reaction [CTSS protein results in increased degradation of CXCL10 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL11 protein]; Chondroitin Sulfates inhibits the reaction [CTSL protein results in increased degradation of CXCL11 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL2 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL2 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [CTSK protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSL protein results in increased cleavage of CXCL1 protein]; Chondroitin Sulfates promotes the reaction [CTSS protein results in increased cleavage of CXCL1 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Chondroitin Sulfates inhibits the reaction [CTSB protein results in increased degradation of CXCL9 protein] |
CTD |
PMID:25833952 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
F12 |
coagulation factor XII |
increases activity |
ISO |
Chondroitin Sulfates analog results in increased activity of F12 protein |
CTD |
PMID:18434646 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein; Chondroitin Sulfates analog binds to FGF10 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866
|
|
G |
Fgf16 |
fibroblast growth factor 16 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF16 protein; Chondroitin Sulfates analog binds to FGF16 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr X:70,816,658...70,828,028
Ensembl chr X:70,817,433...70,878,717
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein; Chondroitin Sulfates analog binds to FGF18 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein; Chondroitin Sulfates analog binds to FGF2 protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Chondroitin Sulfates analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to GDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to HBEGF protein; Chondroitin Sulfates analog binds to HBEGF protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites] |
CTD |
PMID:17605605 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Chondroitin Sulfates] |
CTD |
PMID:25561734 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G |
Klkb1 |
kallikrein B1 |
increases activity |
ISO |
Chondroitin Sulfates analog results in increased activity of KLKB1 protein |
CTD |
PMID:18434646 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Mdk |
midkine |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein; Chondroitin Sulfates analog binds to MDK protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein |
CTD |
PMID:20110869 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein] |
CTD |
PMID:14697411 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein] |
CTD |
PMID:17879260 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein] |
CTD |
PMID:17879260 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein |
CTD |
PMID:17605605 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Genistein inhibits the reaction [Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]] |
CTD |
PMID:16945567 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Genistein inhibits the reaction [Chondroitin Sulfates promotes the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of PDGFRB protein]] |
CTD |
PMID:16945567 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein |
CTD |
PMID:17605605 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein |
CTD |
PMID:17605605 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptn |
pleiotrophin |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein; Chondroitin Sulfates analog binds to PTN protein |
CTD |
PMID:12221095 PMID:15385557 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
affects binding |
ISO |
PTPN11 protein binds to Chondroitin Sulfates |
CTD |
PMID:29794138 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein] |
CTD |
PMID:17879260 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA |
CTD |
PMID:17605605 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF |
CTD |
PMID:14697411 PMID:20110869 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Chondroitin Sulfates] |
CTD |
PMID:25561734 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein Chondroitin Sulfates results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] Chondroitin Sulfates results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:17996099 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to VEGFA protein |
CTD |
PMID:15385557 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to BDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
[Dermatan Sulfate co-treated with SERPIND1 protein] results in decreased activity of F2 protein |
CTD |
PMID:11805133 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein |
CTD |
PMID:15385557 |
|
NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866
|
|
G |
Fgf16 |
fibroblast growth factor 16 |
affects binding |
EXP |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF16 protein |
CTD |
PMID:15385557 |
|
NCBI chr X:70,816,658...70,828,028
Ensembl chr X:70,817,433...70,878,717
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein |
CTD |
PMID:15385557 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects binding increases activity |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein Dermatan Sulfate analog results in increased activity of FGF2 protein |
CTD |
PMID:15385557 PMID:15563459 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Dermatan Sulfate analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases activity |
ISO |
Dermatan Sulfate analog results in increased activity of FGF7 protein |
CTD |
PMID:15563459 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to GDNF protein |
CTD |
PMID:15385557 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to HBEGF protein |
CTD |
PMID:15385557 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Mdk |
midkine |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein |
CTD |
PMID:15385557 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
ISO |
Dermatan Sulfate results in decreased expression of PDGFRA mRNA |
CTD |
PMID:16945567 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
ISO |
Dermatan Sulfate results in decreased expression of PDGFRB mRNA |
CTD |
PMID:16945567 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Ptn |
pleiotrophin |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein |
CTD |
PMID:15385557 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Serpind1 |
serpin family D member 1 |
multiple interactions |
ISO |
[Dermatan Sulfate co-treated with SERPIND1 protein] results in decreased activity of F2 protein |
CTD |
PMID:11805133 |
|
NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects binding |
ISO |
[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to VEGFA protein |
CTD |
PMID:15385557 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein |
CTD |
PMID:27580383 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression increases response to substance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] Dextran Sulfate results in decreased expression of ABCB1A mRNA ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate |
CTD |
PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:29950665 PMID:30701287 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression multiple interactions affects response to substance |
ISO |
Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCC2 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:27580383 PMID:30701287 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression affects response to substance multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein ABCC3 protein affects the susceptibility to Dextran Sulfate [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:27580383 PMID:29950665 PMID:30701287 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions decreases expression |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein |
CTD |
PMID:26271895 PMID:27580383 PMID:29950665 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ABCF2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression affects response to substance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA] Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein ABCG2 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:29950665 PMID:30701287 PMID:38423481 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abi1 |
abl-interactor 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions increases abundance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space |
CTD RGD |
PMID:29950665 PMID:26401072 |
RGD:11555935 |
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA Dextran Sulfate results in decreased activity of ACHE protein |
CTD |
PMID:29950665 PMID:31226429 PMID:31807802 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ackr1 |
atypical chemokine receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:85,782,396...85,784,015
Ensembl chr13:85,782,398...85,783,983
|
|
G |
Ackr2 |
atypical chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:121,559,563...121,573,633
Ensembl chr 8:121,561,211...121,573,582
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Ackr4 |
atypical chemokine receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:104,716,537...104,720,972
Ensembl chr 8:104,716,067...104,723,617
|
|
G |
Acsbg2 |
acyl-CoA synthetase bubblegum family member 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:1,683,846...1,715,517
Ensembl chr 9:1,683,847...1,714,518
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ACSM3 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Actl6a |
actin-like 6A |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:115,492,374...115,508,401
Ensembl chr 2:115,492,285...115,508,401
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actn2 |
actinin alpha 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
|
|
G |
Actr2 |
actin related protein 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ACTR2 protein |
CTD |
PMID:35999755 |
|
NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524
|
|
G |
Actr3 |
actin related protein 3 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ACTR3 protein |
CTD |
PMID:35999755 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Acvr1 |
activin A receptor type 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:42,978,561...43,098,241
|
|
G |
Acy1 |
aminoacylase 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682
|
|
G |
Ada |
adenosine deaminase |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ADA protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression affects response to substance |
ISO |
ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA] ADAM17 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:24548422 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts14 |
ADAM metallopeptidase with thrombospondin type 1 motif, 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866
|
|
G |
Adamts2 |
ADAM metallopeptidase with thrombospondin type 1 motif, 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adcy2 |
adenylate cyclase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236
|
|
G |
Adcy4 |
adenylate cyclase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:29,266,280...29,282,153
Ensembl chr15:29,266,287...29,282,108
|
|
G |
Adcy6 |
adenylate cyclase 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adcy7 |
adenylate cyclase 7 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA Dextran Sulfate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adgra2 |
adhesion G protein-coupled receptor A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ADGRE1 protein flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein] |
CTD |
PMID:38583725 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adgre5 |
adhesion G protein-coupled receptor E5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638
|
|
G |
Adgrf1 |
adhesion G protein-coupled receptor F1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:17,661,258...17,696,359
Ensembl chr 9:17,660,930...17,711,704
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA Dextran Sulfate results in increased expression of ADM mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA |
CTD |
PMID:26271895 PMID:29950665 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA Dextran Sulfate results in decreased expression of AGT mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of AHNAK mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases response to substance |
ISO |
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA] AHR gene mutant form results in increased susceptibility to Dextran Sulfate |
CTD |
PMID:36519841 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahsp |
alpha hemoglobin stabilizing protein |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of AHSP protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AK1 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression increases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AKR1B1 protein Dextran Sulfate results in increased expression of AKR1B1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:29950665 PMID:35093514 PMID:35999755 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:26262998 PMID:36806191 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA |
CTD |
PMID:35093514 PMID:35999755 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ALOX12 protein |
CTD |
PMID:35999755 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases activity |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA Dextran Sulfate results in increased activity of ALPL protein |
CTD |
PMID:29950665 PMID:30489199 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angpt4 |
angiopoietin 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:140,420,389...140,453,583
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ano1 |
anoctamin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Ano10 |
anoctamin 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
|
|
G |
Ano6 |
anoctamin 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G |
Ano7 |
anoctamin 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:93,917,524...93,945,323
|
|
G |
Ano9 |
anoctamin 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:196,197,341...196,229,900
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa4 |
annexin A4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Ap1m1 |
adaptor related protein complex 1 subunit mu 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AP1S1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
affects response to substance multiple interactions |
ISO |
APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16049979 PMID:26262998 PMID:30188895 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcs |
amyloid P component, serum |
increases expression |
ISO |
Dextran Sulfate results in increased expression of APCS protein |
CTD |
PMID:35999755 |
|
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
|
|
G |
Apln |
apelin |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA Dextran Sulfate results in decreased expression of APLN mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Apoa2 |
apolipoprotein A2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein |
CTD |
PMID:35999755 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of APOA4 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein] |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoe |
apolipoprotein E |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of APOE protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp11 |
aquaporin 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:152,046,517...152,056,725
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp8 |
aquaporin 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA Dextran Sulfate results in increased expression of AR mRNA |
CTD |
PMID:27920257 PMID:29950665 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARF3 protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G |
Arg1 |
arginase 1 |
multiple interactions decreases expression |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein] Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein |
CTD |
PMID:25026504 PMID:38164749 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARHGAP1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739
|
|
G |
Arhgap25 |
Rho GTPase activating protein 25 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982
|
|
G |
Arhgap40 |
Rho GTPase activating protein 40 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARHGDIA protein |
CTD |
PMID:35999755 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression decreases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ARHGDIB mRNA Dextran Sulfate results in decreased expression of ARHGDIB protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA |
CTD |
PMID:23894361 PMID:29950665 PMID:35999755 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
|
|
G |
Arhgef6 |
Rac/Cdc42 guanine nucleotide exchange factor 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304
|
|
G |
Arl3 |
ADP ribosylation factor like GTPase 3 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ARL3 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820
|
|
G |
Arl9 |
ADP-ribosylation factor like GTPase 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ARL9 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARPC2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471
|
|
G |
Arpc3 |
actin related protein 2/3 complex, subunit 3 |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein Dextran Sulfate results in decreased expression of ARPC3 protein |
CTD |
PMID:35999755 |
|
NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARPC4 protein |
CTD |
PMID:35999755 |
|
NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Arsb |
arylsulfatase B |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARSB mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Asic4 |
acid sensing ion channel subunit family member 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ASS1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA] |
CTD |
PMID:27611972 PMID:31676321 PMID:35439472 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]] |
CTD |
PMID:31676321 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atic |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ATIC protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889
|
|
G |
Atp10a |
ATPase phospholipid transporting 10A (putative) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:109,556,760...109,730,440
Ensembl chr 1:109,556,782...109,730,437
|
|
G |
Atp11b |
ATPase phospholipid transporting 11B (putative) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp1a4 |
ATPase Na+/K+ transporting subunit alpha 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:84,683,766...84,719,790
Ensembl chr13:84,683,768...84,719,687
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp2c2 |
ATPase secretory pathway Ca2+ transporting 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368
|
|
G |
Atp4b |
ATPase H+/K+ transporting subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:76,144,150...76,153,063
Ensembl chr16:76,144,150...76,153,063
|
|
G |
Atp6v0a2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Atp6v1e2 |
ATPase H+ transporting V1 subunit E2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:7,667,564...7,672,626
|
|
G |
Atp6v1f |
ATPase H+ transporting V1 subunit F |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ATP6V1F mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:58,067,666...58,070,628
|
|
G |
Atp6v1g3 |
ATPase H+ transporting V1 subunit G3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:49,800,256...49,825,247
Ensembl chr13:49,794,222...49,825,247
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989
|
|
G |
Axin2 |
axin 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein] |
CTD |
PMID:31715269 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
B3gnt3 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:18,401,405...18,410,821
Ensembl chr16:18,401,405...18,410,766
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of B3GNT7 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
B3gnt8 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,135,602...81,138,501
Ensembl chr 1:81,135,499...81,142,263
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Banf1 |
BAF nuclear assembly factor 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BANK1 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein] |
CTD |
PMID:24146755 PMID:37209277 PMID:38583725 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein Dextran Sulfate results in decreased activity of BCHE protein |
CTD |
PMID:31226429 PMID:31807802 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein] |
CTD |
PMID:25449198 PMID:37209277 PMID:38583725 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]] |
CTD |
PMID:38164749 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bcl7c |
BAF chromatin remodeling complex subunit BCL7C |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BCL7C mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] |
CTD |
PMID:27611972 PMID:31676321 PMID:31926917 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Best1 |
bestrophin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063
|
|
G |
Bgn |
biglycan |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bin2 |
bridging integrator 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of BIN2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein] |
CTD |
PMID:25449198 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of BIRC6 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmp10 |
bone morphogenetic protein 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,872,066...119,877,694
Ensembl chr 4:119,872,045...119,878,627
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Bpifa1 |
BPI fold containing family A, member 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:142,627,810...142,633,553
Ensembl chr 3:142,627,810...142,633,552
|
|
G |
Bspry |
B-box and SPRY domain containing |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BSPRY mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180
|
|
G |
Btf3l4 |
basic transcription factor 3-like 4 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of BTF3L4 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866
|
|
G |
C1galt1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831
|
|
G |
C1galt1c1 |
C1GALT1-specific chaperone 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787
|
|
G |
C1qa |
complement C1q A chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qb |
complement C1q B chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C1qtnf6 |
C1q and TNF related 6 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of C1QTNF6 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 7:110,077,867...110,084,584
Ensembl chr 7:110,077,878...110,084,412
|
|
G |
C1s |
complement C1s |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
C4b |
complement C4B |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
C4bpa |
complement component 4 binding protein, alpha |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein |
CTD |
PMID:35999755 |
|
NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205
|
|
G |
C5ar1 |
complement C5a receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Cab39 |
calcium binding protein 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calcb |
calcitonin-related polypeptide, beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calm2 |
calmodulin 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CALM2 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CALR protein |
CTD |
PMID:35999755 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CAP1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Capn13 |
calpain 13 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 6:22,071,845...22,166,864
Ensembl chr 6:22,071,845...22,166,850
|
|
G |
Capzb |
capping actin protein of muscle Z-line subunit beta |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CAPZB protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Car4 |
carbonic anhydrase 4 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases expression |
ISO EXP |
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein] celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]] Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein |
CTD |
PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases activity multiple interactions |
ISO |
Dextran Sulfate results in increased cleavage of CASP3 protein Dextran Sulfate results in increased activity of CASP3 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein] |
CTD |
PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 PMID:37209277 PMID:38583725 PMID:38648921 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions decreases expression |
ISO |
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein] |
CTD |
PMID:29496522 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
decreases activity increases activity multiple interactions |
ISO |
Dextran Sulfate results in decreased activity of CAT protein Dextran Sulfate results in increased activity of CAT protein [Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein] |
CTD |
PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cavin2 |
caveolae associated protein 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CAVIN2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147
|
|
G |
Cbr1 |
carbonyl reductase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CBR1 protein |
CTD |
PMID:35999755 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC12 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417
|
|
G |
Ccdc124 |
coiled-coil domain containing 124 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC124 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564
|
|
G |
Ccdc13 |
coiled-coil domain containing 13 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC13 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 8:121,455,202...121,507,487
Ensembl chr 8:121,457,697...121,502,337
|
|
G |
Ccdc158 |
coiled-coil domain containing 158 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CCDC158 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein] |
CTD |
PMID:32272095 |
|
NCBI chr14:15,411,178...15,468,579
Ensembl chr14:15,411,163...15,468,581
|
|
G |
Ccdc88b |
coiled-coil domain containing 88B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC88B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:204,036,913...204,052,878
Ensembl chr 1:204,036,918...204,052,970
|
|
G |
Ccdc9 |
coiled-coil domain containing 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC9 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:76,978,312...76,991,673
Ensembl chr 1:76,974,091...76,991,607
|
|
G |
Ccdc96 |
coiled-coil domain containing 96 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC96 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888
|
|
G |
Cchcr1 |
coiled-coil alpha-helical rod protein 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCHCR1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases secretion increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased secretion of CCL11 protein Dextran Sulfate results in increased expression of CCL11 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein] |
CTD |
PMID:21858153 PMID:29950665 PMID:32033881 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression increases secretion |
ISO |
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein] |
CTD |
PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 PMID:31807802 PMID:38583725 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCL27A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO EXP |
Dextran Sulfate results in increased expression of CCL3 mRNA ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA] Dextran Sulfate results in increased expression of CCL3 protein Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein] |
CTD |
PMID:19645018 PMID:30811821 PMID:33130971 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CCL7 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA] |
CTD |
PMID:19645018 PMID:29950665 PMID:32033881 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression decreases expression |
ISO |
Dextran Sulfate results in increased expression of CCL6 mRNA Dextran Sulfate results in decreased expression of CCL6 mRNA |
CTD |
PMID:19645018 PMID:35093514 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein] |
CTD |
PMID:31715269 PMID:35439472 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein] |
CTD |
PMID:36265525 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G |
Ccrl2 |
C-C motif chemokine receptor like 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664
|
|
G |
Ccsap |
centriole, cilia and spindle-associated protein |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCSAP mRNA |
CTD |
PMID:35093514 |
|
NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753
|
|
G |
Cd14 |
CD14 molecule |
affects response to substance multiple interactions |
ISO |
Dextran Sulfate affects the susceptibility to CD14 protein [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA] |
CTD |
PMID:28411859 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd163 |
CD163 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD163 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd177 |
CD177 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD177 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621
|
|
G |
Cd180 |
CD180 molecule |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CD180 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA |
CTD |
PMID:23894361 PMID:29950665 |
|
NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936
|
|
G |
Cd19 |
CD19 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD19 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd247 |
Cd247 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd34 |
CD34 molecule |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CD34 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,668,878...157,695,366
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd52 |
CD52 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD52 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd53 |
Cd53 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD53 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice |
RGD |
PMID:25004394 |
RGD:40925931 |
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd72 |
Cd72 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD72 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725
|
|
G |
Cd74 |
CD74 molecule |
increases expression decreases expression |
ISO |
Dextran Sulfate results in increased expression of CD74 mRNA Dextran Sulfate results in decreased expression of CD74 mRNA |
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd79a |
CD79a molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD79A mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935
|
|
G |
Cd79b |
CD79b molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD79B mRNA |
CTD |
PMID:23894361 |
|
NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625
|
|
G |
Cd81 |
Cd81 molecule |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CD81 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein] Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein |
CTD |
PMID:29950665 PMID:38164749 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cda |
cytidine deaminase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO |
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein |
CTD |
PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions increases expression |
ISO |
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein |
CTD |
PMID:34273909 PMID:36543318 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdhr2 |
cadherin-related family member 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CDHR2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr17:9,876,853...9,913,356
Ensembl chr17:9,876,860...9,912,575
|
|
G |
Cdk11b |
cyclin-dependent kinase 11B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CDK11B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:166,212,761...166,238,883
Ensembl chr 5:166,212,829...166,238,876
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression decreases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CDX2 protein Dextran Sulfate results in decreased expression of CDX2 protein 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein] |
CTD |
PMID:29680209 PMID:38663798 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CEBPD mRNA |
CTD |
PMID:35093514 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cel |
carboxyl ester lipase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cep131 |
centrosomal protein 131 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CEP131 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:105,346,015...105,370,380
Ensembl chr10:105,346,015...105,370,380
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA Dextran Sulfate results in decreased expression of CES1D mRNA |
CTD |
PMID:29950665 PMID:35093514 PMID:35999755 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Ces2e |
carboxylesterase 2E |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856
|
|
G |
Cfap45 |
cilia and flagella associated protein 45 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CFAP45 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein |
CTD |
PMID:35999755 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfd |
complement factor D |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CFD protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cfh |
complement factor H |
multiple interactions increases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein] Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein |
CTD |
PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755 |
|
NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838
|
|
G |
Cfl1 |
cofilin 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CFL1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein] |
CTD |
PMID:25449198 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHAF1A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein] |
CTD |
PMID:32272095 |
|
NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507
|
|
G |
Chmp2a |
charged multivesicular body protein 2A |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CHMP2A protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:73,660,045...73,662,894
Ensembl chr 1:73,660,046...73,662,452
|
|
G |
Chmp4b |
charged multivesicular body protein 4B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHMP4B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:143,170,859...143,211,376
Ensembl chr 3:143,170,902...143,210,844
|
|
G |
Chn2 |
chimerin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
|
|
G |
Chrdl2 |
chordin-like 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHRDL2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CHUK protein modified form notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckb |
creatine kinase B |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CKB protein |
CTD |
PMID:35999755 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CKM protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clca4 |
chloride channel accessory 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CLCA4 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Clcn2 |
chloride voltage-gated channel 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:80,197,741...80,211,657
Ensembl chr11:80,198,153...80,211,657
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions increases expression decreases expression |
ISO |
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein] |
CTD |
PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn11 |
claudin 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions increases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein |
CTD |
PMID:26271895 PMID:29680209 PMID:36543318 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CLEC10A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CLIC1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein |
CTD |
PMID:35999755 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cma1 |
chymase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125
|
|
G |
Cmpk1 |
cytidine/uridine monophosphate kinase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CMPK1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:128,480,301...128,507,830
Ensembl chr 5:128,480,301...128,507,830
|
|
G |
Cnga4 |
cyclic nucleotide gated channel subunit alpha 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:159,752,357...159,756,375
|
|
G |
Cnn2 |
calponin 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CNN2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases response to substance increases expression multiple interactions |
ISO |
CNR1 results in decreased susceptibility to Dextran Sulfate Dextran Sulfate results in increased expression of CNR1 protein SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein] |
CTD |
PMID:15085199 PMID:27920472 PMID:30611738 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions increases response to substance affects response to substance increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein] CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate CNR2 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntfr |
ciliary neurotrophic factor receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cog1 |
component of oligomeric golgi complex 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:98,695,481...98,708,495
Ensembl chr10:98,695,423...98,709,292
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col16a1 |
collagen type XVI alpha 1 chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of COL16A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA Dextran Sulfate results in decreased expression of COL1A1 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of COL1A2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col22a1 |
collagen type XXII alpha 1 chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of COL22A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462
|
|
G |
Col23a1 |
collagen type XXIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314
|
|
G |
Col28a1 |
collagen type XXVIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:36,069,970...36,223,220
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of COL3A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein] Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein |
CTD |
PMID:32272095 PMID:35093514 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein] |
CTD |
PMID:32272095 PMID:35093514 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Coro1a |
coronin 1A |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CORO1A protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Coro1c |
coronin 1C |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CORO1C protein |
CTD |
PMID:35999755 |
|
NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of COTL1 protein |
CTD |
PMID:35999755 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of COX5B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpa1 |
carboxypeptidase A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544
|
|
G |
Cpb2 |
carboxypeptidase B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556
|
|
G |
Cr2 |
complement C3d receptor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CR2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235
|
|
G |
Cracd |
capping protein inhibiting regulator of actin dynamics |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CRACD mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Crisp1 |
cysteine-rich secretory protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CRISP1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796
|
|
G |
Crtap |
cartilage associated protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein] |
CTD |
PMID:15652231 PMID:29950665 PMID:31442584 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CSF3 mRNA Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA] |
CTD |
PMID:32033881 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csf3r |
colony stimulating factor 3 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:138,298,605...138,318,224
Ensembl chr 5:138,301,506...138,317,881
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CTNNB1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] |
CTD |
PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CTPS1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CTSC mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cubn |
cubilin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:16,982,864...17,030,078
Ensembl chr11:16,982,860...17,030,046
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA] |
CTD |
PMID:25026504 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CXCL12 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CXCL13 mRNA |
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein] Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein |
CTD |
PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases secretion increases expression |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein] Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein |
CTD |
PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 PMID:31807802 PMID:34273909 PMID:34998820 PMID:36519841 More...
|
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA Dextran Sulfate results in increased expression of CXCL5 mRNA |
CTD |
PMID:19645018 PMID:29950665 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CXCL9 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYBA protein |
CTD |
PMID:20637373 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein |
CTD |
PMID:20637373 PMID:23894361 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyfip1 |
cytoplasmic FMR1 interacting protein 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein |
CTD |
PMID:29680209 PMID:34998820 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
EXP |
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen |
CTD |
PMID:28438436 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYP24A1 protein |
CTD |
PMID:38588969 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP26B1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA Dextran Sulfate results in decreased expression of CYP27B1 protein |
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
EXP |
Dextran Sulfate results in decreased activity of CYP2B1 protein [Dextran Sulfate results in decreased activity of CYP2B1 protein] which results in decreased chemical synthesis of hydroxybupropion |
CTD |
PMID:28438436 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
EXP |
Dextran Sulfate results in decreased activity of CYP2E1 protein [Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone |
CTD |
PMID:28438436 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2r1 |
cytochrome P450, family 2, subfamily r, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein] |
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp4f39 |
cytochrome P450, family 4, subfamily f, polypeptide 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:27580383 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of DBT protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609
|
|
G |
Dcn |
decorin |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DEPP1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Derl3 |
derlin 3 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DERL3 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dgki |
diacylglycerol kinase, iota |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of DHCR24 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DHRS9 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Dhrsx |
dehydrogenase/reductase X-linked |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DHRSX mRNA |
CTD |
PMID:35093514 |
|
NCBI chr12:16,299,768...16,304,553
Ensembl chr12:16,299,808...16,304,552
|
|
G |
Dkk2 |
dickkopf WNT signaling pathway inhibitor 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dmpk |
DM1 protein kinase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G |
Dmrta1 |
DMRT-like family A1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of DMRTA1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:104,415,893...104,422,433
Ensembl chr 5:104,415,893...104,422,433
|
|
G |
Dmwd |
DM1 locus, WD repeat containing |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DMWD mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:78,722,436...78,729,224
Ensembl chr 1:78,722,330...78,740,593
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of DNAJC10 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719
|
|
G |
Dnm1 |
dynamin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538
|
|
G |
Dnm3 |
dynamin 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108
|
|
G |
Dok2 |
docking protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402
|
|
G |
Dpep1 |
dipeptidase 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of DPEP1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein] |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257
|
|
G |
Dpep2 |
dipeptidase 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Drap1 |
Dr1 associated protein 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DRAP1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:202,731,775...202,734,468
Ensembl chr 1:202,731,788...202,734,425
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774
|
|
G |
Dtx1 |
deltex E3 ubiquitin ligase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:35,849,647...35,880,835
Ensembl chr12:35,849,617...35,880,838
|
|
G |
Duoxa2 |
dual oxidase maturation factor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DUOXA2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 3:109,245,337...109,249,055
Ensembl chr 3:109,245,476...109,248,968
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions increases expression |
ISO |
DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate] Dextran Sulfate results in increased expression of DUSP1 mRNA |
CTD |
PMID:30844440 PMID:35093514 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ECPAS protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
|
|
G |
Eda |
ectodysplasin-A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
|
|
G |
Edf1 |
endothelial differentiation-related factor 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EDF1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:8,377,058...8,381,363
Ensembl chr 3:8,366,613...8,381,363
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of EDN2 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA |
CTD |
PMID:16216902 PMID:29950665 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EEF1G protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Efemp2 |
EGF containing fibulin extracellular matrix protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414
|
|
G |
Efhd2 |
EF-hand domain family, member D2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EFHD2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egln2 |
egl-9 family hypoxia-inducible factor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EGLN2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751
|
|
G |
Ehd1 |
EH-domain containing 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EHD1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212
|
|
G |
Ehd4 |
EH-domain containing 4 |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein Dextran Sulfate results in decreased expression of EHD4 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EHMT2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions increases phosphorylation |
ISO |
EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein] |
CTD |
PMID:27920257 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EIF5A protein |
CTD |
PMID:35999755 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EIF5B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Elane |
elastase, neutrophil expressed |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185
|
|
G |
Emc2 |
ER membrane protein complex subunit 2 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 7:74,587,196...74,624,163
Ensembl chr 7:74,587,175...74,625,189
|
|
G |
Emp2 |
epithelial membrane protein 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EMP2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Eng |
endoglin |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ENG mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ENO1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Eno3 |
enolase 3 |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein] |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Enpep |
glutamyl aminopeptidase |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EPHX1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ereg |
epiregulin |
decreases response to substance increases expression |
ISO |
EREG protein results in decreased susceptibility to Dextran Sulfate dextran sodium sulfate increases expression of Ereg protein in colonic mucosa |
CTD RGD |
PMID:15456865 PMID:20498653 |
RGD:39457688 |
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ERRFI1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esam |
endothelial cell adhesion molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ESR1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:29950665 PMID:30270565 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA] |
CTD |
PMID:30270565 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Evl |
Enah/Vasp-like |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344
|
|
G |
Ewsr1 |
EWS RNA-binding protein 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EWSR1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F11 |
coagulation factor XI |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein |
CTD |
PMID:35999755 |
|
NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions |
ISO |
[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein |
CTD |
PMID:30611738 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein] |
CTD |
PMID:26271895 PMID:32272095 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FADS1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FADS2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam229a |
family with sequence similarity 229, member A |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FAM229A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:141,829,716...141,830,705
Ensembl chr 5:141,828,664...141,830,705
|
|
G |
Fam50b |
family with sequence similarity 50, member B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FAM50B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr17:30,174,431...30,193,627
Ensembl chr17:30,174,411...30,193,615
|
|
G |
Fam98b |
family with sequence similarity 98, member B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FAM98B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:104,134,803...104,164,249
Ensembl chr 3:104,134,824...104,163,704
|
|
G |
Fau |
FAU ubiquitin like and ribosomal protein S30 fusion |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742
|
|
G |
Fbln2 |
fibulin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G |
Fbln5 |
fibulin 5 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA Dextran Sulfate results in decreased expression of FBLN5 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755
|
|
G |
Fbn1 |
fibrillin 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxo2 |
F-box protein 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FBXO2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fcer1g |
Fc epsilon receptor Ig |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443
|
|
G |
Fcgr1a |
Fc gamma receptor 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Fcgr3a |
Fc gamma receptor 3A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fdxr |
ferredoxin reductase |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FDXR mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fermt3 |
FERM domain containing kindlin 3 |
increases expression decreases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of FERMT3 protein Dextran Sulfate results in decreased expression of FERMT3 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results |